155 related articles for article (PubMed ID: 36270111)
21. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA
Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065
[TBL] [Abstract][Full Text] [Related]
22. Phthalazone tethered 1,2,3-triazole conjugates: In silico molecular docking studies, synthesis, in vitro antiproliferative, and kinase inhibitory activities.
Abdelgawad MA; Bukhari SNA; Musa A; Elmowafy M; Nayl AA; El-Ghorab AH; Sadek Abdel-Bakky M; Omar HA; Hadal Alotaibi N; Hassan HM; Ghoneim MM; Bakr RB
Bioorg Chem; 2023 Apr; 133():106404. PubMed ID: 36812829
[TBL] [Abstract][Full Text] [Related]
23. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors.
Farouk AKBAW; Abdelrasheed Allam H; Rashwan E; George RF; Abbas SE
Bioorg Chem; 2022 Nov; 128():106099. PubMed ID: 35994884
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of guaianolide-germacranolide heterodimers as novel anticancer agents against hepatocellular carcinoma.
Yan JX; Li QH; Li TZ; Huang ZY; Ma YB; Chen JJ
Drug Dev Res; 2023 Sep; 84(6):1285-1298. PubMed ID: 37345274
[TBL] [Abstract][Full Text] [Related]
27. 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
El-Adl K; Sakr H; Nasser M; Alswah M; Shoman FMA
Arch Pharm (Weinheim); 2020 Sep; 353(9):e2000079. PubMed ID: 32515896
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold.
Hassan A; Badr M; Abdelhamid D; Hassan HA; Abourehab MAS; Abuo-Rahma GEA
Bioorg Chem; 2022 Mar; 120():105631. PubMed ID: 35091289
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis of novel chromene-based scaffolds targeting hepatocellular carcinoma: Cell cycle arrest, cytotoxic effect against resistant cancer cells, apoptosis induction, and c-Src inhibition.
Abdelall EKA; Elshemy HAH; Labib MB; Mohamed FEA
Drug Dev Res; 2024 Feb; 85(1):e22133. PubMed ID: 37971069
[TBL] [Abstract][Full Text] [Related]
30. The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia.
Othman EM; Fayed EA; Husseiny EM; Abulkhair HS
Bioorg Chem; 2022 Oct; 127():105968. PubMed ID: 35728289
[TBL] [Abstract][Full Text] [Related]
31. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and Preclinical Evaluation of Indole Triazole Conjugates as Microtubule Targeting Agents that are Effective against MCF-7 Breast Cancer Cell Lines.
Yele V; Pindiprolu SKSS; Sana S; Ramamurty DSVNM; Madasi JRK; Vadlamani S
Anticancer Agents Med Chem; 2021; 21(8):1047-1055. PubMed ID: 32981511
[TBL] [Abstract][Full Text] [Related]
33. Novel VEGFR-2 inhibitors as antiangiogenic and apoptotic agents via paracrine and autocrine cascades: Design, synthesis, and biological evaluation.
Abdel Rahman DE; Fouad MA; Mohammed ER; El-Zoheiry HH; Abdelrasheed Allam H
Bioorg Chem; 2023 Oct; 139():106678. PubMed ID: 37354661
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological evaluation of some new 1,3,4-thiadiazine-thiourea derivatives as potential antitumor agents against non-small cell lung cancer cells.
Ragab FAF; Abdel-Aziz SA; Kamel M; Ouf AMA; Allam HA
Bioorg Chem; 2019 Dec; 93():103323. PubMed ID: 31586713
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, in vitro anticancer and antibacterial activities and in silico studies of new 4-substituted 1,2,3-triazole-coumarin hybrids.
Kraljević TG; Harej A; Sedić M; Pavelić SK; Stepanić V; Drenjančević D; Talapko J; Raić-Malić S
Eur J Med Chem; 2016 Nov; 124():794-808. PubMed ID: 27639370
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and biological characteristics of pyrazolo[3,4-
Ying DX; Wang J; Li XF; Zhang W; Rao GW
Future Med Chem; 2022 Nov; 14(22):1649-1662. PubMed ID: 36317642
[No Abstract] [Full Text] [Related]
37. Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
Zhai S; Zhang H; Chen R; Wu J; Ai D; Tao S; Cai Y; Zhang JQ; Wang L
Eur J Med Chem; 2021 Dec; 225():113824. PubMed ID: 34509167
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of novel nicotinic acid derivatives of potential antioxidant and anticancer activity.
El-Dash Y; Khalil NA; Ahmed EM; Hassanin SO; Gowifel AMH; Hassan MSA
Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300250. PubMed ID: 37792247
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR-2 inhibitors.
El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH
Arch Pharm (Weinheim); 2022 Jan; 355(1):e2100278. PubMed ID: 34596910
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of Sorafenib-Ruthenium Complexes, Investigation of Biological Activities and Applications in Drug Delivery Systems as an Anticancer Agent.
Zengin Kurt B; Öztürk Civelek D; Çakmak EB; Kolcuoğlu Y; Şenol H; Sağlık Özkan BN; Dag A; Benkli K
J Med Chem; 2024 Mar; 67(6):4463-4482. PubMed ID: 38471014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
